Piper Sandler has recently reduced Xeris Biopharma Holdings Inc (XERS) stock to Neutral rating, as announced on November 11, 2024, according to Finviz. Earlier, on March 28, 2024, Oppenheimer had initiated the stock to Outperform, setting a price target of $5. Craig Hallum also initiated Buy rating with a price target of $4.50. Additionally, Jefferies initiated Buy rating on October 21, 2022, with a target price of $4. Craig Hallum analysts, in their report published on April 28, 2022, also initiated Buy rating and set a price target of $6.50 for Xeris Biopharma Holdings Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Xeris Biopharma Holdings Inc (XERS) Stock Trading Recap
On Tuesday, Xeris Biopharma Holdings Inc (XERS) stock saw a modest uptick, ending the day at $3.42 which represents a slight increase of $0.04 or 1.18% from the prior close of $3.38. The stock opened at $3.32 and touched a low of $3.3 during the day, reaching a high of $3.43. The volume of shares traded was 3.63 million exceeding the average volume of 1.61 million.
Sponsored
XERS Stock Performance and Moving Averages
In recent trading, Xeris Biopharma Holdings Inc (XERS) stock price has shown some volatility, fluctuating 11.04% over the last five trades and 5.88% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 47.41%, and it has gained 29.55% in the previous three months. Currently, XERS is trading at 7.09%, 10.92%, and 36.11% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, XERS, a Healthcare sector stock, is trading -6.04% below its 52-week high but remains 102.37% above its 52-week low. The Average True Range (ATR) (14 days) of 0.16 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Xeris Biopharma Holdings Inc’s Profitability and Valuation Ratios
Xeris Biopharma Holdings Inc’s profitability metrics reveal financial health. The company currently boasts an operating margin of -24.11% and a profit margin of -33.69%, with a gross margin of 47.41%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Xeris Biopharma Holdings Inc’s market capitalization stands at $509.86 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 2.72, reflecting the market’s valuation of the company’s sales.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.00% of Xeris Biopharma Holdings Inc (XERS)’s shares, while financial institutions hold 43.57%.
